​

Orchestra BioMed (OBIO) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

OBIO Stock Forecast


Orchestra BioMed (OBIO) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $10.00, with a high of $10.00 and a low of $10.00. This represents a 43.47% increase from the last price of $6.97.

$3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $10 Low: $10 Last Closed Price: $6.97

OBIO Stock Rating


Orchestra BioMed stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

OBIO Price Target Upside V Benchmarks


TypeNameUpside
StockOrchestra BioMed43.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts-25
Avg Price Target-$10.00$11.00
Last Closing Price$6.97$6.97$6.97
Upside/Downside-43.47%57.82%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2616---7
Oct, 2616---7
Sep, 26151--7
Aug, 26151--7
Jul, 26151--7
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 05, 2026Yi ChenH.C. Wainwright$10.00$5.9568.07%43.47%
Sep 10, 2026Marie ThibaultBTIG$10.00$5.4583.49%43.47%
Aug 11, 2026Matt O'BrienPiper Sandler$10.00$4.46124.22%43.47%
May 13, 2026Matt MiksicBarclays$13.00$4.06220.20%86.51%
Jan 09, 2026Matt MiksicBarclays$12.00$4.84147.93%72.17%
Mar 20, 2025Marie ThibaultBTIG$12.00$4.35175.86%72.17%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2026BTIGBuyBuyhold
Oct 15, 2026Piper SandlerOverweightOverweighthold
Oct 05, 2026H.C. WainwrightBuyBuyhold
Sep 15, 2026B. RileyBuyBuyhold
Sep 10, 2026BTIGBuyBuyupgrade
Aug 11, 2026Piper SandlerOverweightOverweighthold
May 13, 2026BarclaysOverweightOverweighthold
Jan 09, 2026BarclaysOverweightOverweighthold
Dec 10, 2025Cowen & Co.Buyinitialise
Sep 04, 2025H.C. WainwrightBuyBuyhold

Financial Forecast


EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.32$-1.48$-1.66$-1.11---
Avg Forecast$-13.86$-1.48$-1.66$-1.92$-1.72$-1.66$-0.99
High Forecast$-9.43$-1.44$-1.65$-1.69$-1.06$-1.03$-0.61
Low Forecast$-18.00$-1.51$-1.67$-2.06$-2.39$-2.31$-1.38
Surprise %-90.48%---42.19%---

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.53M$2.76M$2.64M$33.48M---
Avg Forecast$4.30M$3.53M$3.19M$3.84M$3.89M$4.02M$27.27M
High Forecast$5.29M$4.33M$3.37M$5.01M$5.07M$5.24M$35.49M
Low Forecast$3.25M$2.72M$2.78M$2.71M$2.75M$2.84M$19.25M
Surprise %-17.93%-21.78%-17.24%770.93%---

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.61M$-49.12M$-61.02M$-52.95M---
Avg Forecast$-460.50M$-49.12M$-55.12M$-62.30M$-69.45M$-64.38M$-32.89M
High Forecast$-313.17M$-47.95M$-54.78M$-56.25M$-35.23M$-34.06M$-20.31M
Low Forecast$-598.07M$-50.25M$-55.45M$-68.35M$-79.40M$-76.78M$-45.79M
Surprise %-92.70%-10.72%-15.00%---

OBIO Forecast FAQ


Is Orchestra BioMed stock a buy?

Orchestra BioMed stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Orchestra BioMed is a favorable investment for most analysts.

What is Orchestra BioMed's price target?

Orchestra BioMed's price target, set by 6 Wall Street analysts, averages $10 over the next 12 months. The price target range spans from $10 at the low end to $10 at the high end, suggesting a potential 43.47% change from the previous closing price of $6.97.

How does Orchestra BioMed stock forecast compare to its benchmarks?

Orchestra BioMed's stock forecast shows a 43.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Orchestra BioMed over the past three months?

  • November 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Orchestra BioMed’s EPS forecast?

Orchestra BioMed's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.72, marking a 54.95% increase from the reported $-1.11 in 2025. Estimates for the following years are $-1.66 in 2027, and $-0.99 in 2028.

What is Orchestra BioMed’s revenue forecast?

Orchestra BioMed's average annual revenue forecast for its fiscal year ending in December 2026 is $3.89M, reflecting a -88.37% decrease from the reported $33.48M in 2025. The forecast for 2027 is $4.02M, and $27.27M for 2028.

What is Orchestra BioMed’s net income forecast?

Orchestra BioMed's net income forecast for the fiscal year ending in December 2026 stands at $-69.451M, representing an 31.15% increase from the reported $-52.955M in 2025. Projections indicate $-64.384M in 2027, and $-32.893M in 2028.